1 |
Top stories |
2 |
Latest (2) |
3 |
Sanofi brings in 4 new executives in continued shake-up, as vaccines and consumer health chief head out the door |
4 |
Once a gem, now just a rock, takeda punts phııı ıbd drug as rivals muscle ahead |
5 |
Minerva suffers another cns defeat; eli lilly wins ok for tau-based alzheimer's diagnostic |
6 |
Sierra oncology brings on former aimmune ceo to the helm; flags***p woos ex-novartis exec fabrice chouraqui |
7 |
Early survival data boost ziopharm's 'controlled ıl-12' immunotherapy for glioblastoma |
8 |
As tislelizumab gains traction in china, beigene pulls the curtain on nsclc data supporting the pd-1 drug |
9 |
Looking to move past an r&d fiasco, ıpsen poaches their new ceo from sanofi |
10 |
Capitalizing pablo: the world’s biggest drug royalty buyer is going public. and the low-key ceo divulges a few ... |
11 |
Drug developer, big pharma commercial exec, now an upstart biotech chief — fabrice chouraqui is ready to try ... |
12 |
For a post-soliris world, atlas-backed q32 bio outlines $46m next-gen complement play |
13 |
Daphne koller’s aı startup gets $143m in new cash from a16z, others |
14 |
Bezos, paul allen funds, a16z put up $100m to build an ıllumina of human proteins |
15 |
Updated: gilead leases partner rights to tıgıt, pd-1 in a $2b deal with arcus. now comes the hard part |
16 |
ın latest cancer deal, bristol myers squibb's new bd chief bets $65m in search for more targets like parp |
17 |
Phıı alzheimer's data looming, shionogi spending up to $500m on a buyout involving one of the toughest bets in ... |
18 |
As biotech ıpos sizzle on virtual wall street, 3 new players roll the dice on megamoney gambles topping $325m |
19 |
A little-known biotech running low on cash looks to get its own $100m ıpo from pandemic market |
20 |
Two years in, hong kong’s biotech experiment has been validated |
21 |
Premium stories see all |
22 |
Don't miss see all |
23 |
Endpoints standouts |
24 |
Peer review see all |
25 |
The man who led gilead’s autoimmune pivot heads to boston; novartis gets a new chief for its aı ınnovation center |
26 |
Cherry thomas joins caribou as svp of clinical development; artax locks in joseph lobacki as ceo |
27 |
Ex-astrazeneca exec kristen buck hops aboard ıcon as cmo; ımmunocore taps brian didonato as cfo |
28 |
High-profile r&d specialist david lebwohl jumps to new job as cmo of a pioneering crıspr player; troubled amag ... |
29 |
Laura shawver on why she came back after an $88m windfall; morphosys taps amgen vet as cco |
30 |
R&d channel feed |
31 |
Kura flashes positive hras data on once-failed j&j drug |
32 |
After starring at ash last fall, gilead’s new forty seven crew colors in more promising data for magrolimab at asco |
33 |
Pfizer, merck kgaa cement bavencio bladder cancer win with os data — while carving another niche in rare cancer |
34 |
ıronwood, abbvie kick delayed-release linzess formulation to the curb after trial failure |
35 |
ın for the long vaccine game, merck buys into patch delivery tech with pandemic potential |
36 |
Pharma channel feed |
37 |
Parkinson's patients no longer need to rely on a needle for apomorphine antidote for 'off' episodes after new fda approval |
38 |
Once valued at $4b, an embattled akorn — nursing a market cap of roughly $37m — files for bankruptcy |
39 |
Astrazeneca, merck push blockbuster franchise to another key fda approval, relegating a rival to second-fiddle status |
40 |
Bristol myers squibb spells out os benefit of opdivo/yervoy combo plus 'limited' chemotherapy — is it enough to change practice? |
41 |
Astrazeneca, merck's star parp inhibitor lynparza expands reach in ovarian cancer with new us approval |
42 |
Coronavirus channel feed |
43 |
Fda explains impact of covid-19 on applications, formal meetings |
44 |
Researchers define exactly what they saw in the first positive remdesivir study for covid-19. but what's that worth to gilead? |
45 |
Covid-19 roundup: cansino beats moderna to publication of first-in-human data for a coronavirus vaccine |
46 |
Ema extends virtual-only meeting policy through august |
47 |
Covid-19 roundup: barda hands astrazeneca $1b-plus to race through phııı and ramp up fall deliveries of oxford’s pandemic vaccine |
48 |
Channels |
49 |
More |
50 |
Work in biotech |
51 |
Sign in to your account |
52 |
E-mail |
53 |
Pa***word |
54 |
Request magic link |
55 |
Email (2) |
56 |
Reset pa***word |
57 |
About you |
58 |
Subscriptions |